HDAX Therapeutics’ Post

INOVIQ Ltd (ASX:IIQ) is pleased to announce the successful completion of the share purchase plan (SPP) with applications accepted for A$2.379 million. ✔ IIQ successfully completed its SPP with applications totalling A$7.29m, exceeding its target of A$2m. ✔ Directors accepted allocations to the maximum of A$2.379m, with scale back on a pro-rata basis. ✔ Total capital raised of A$9.379m under the SPP and recent placement (A$7m) to institutional and sophisticated investors. ✔ Investors in the Placement & SPP received one free quoted option for every two new Shares issued with an exercise price of $1.00 and expiry of 8 July 2026. ✔ INOVIQ now has a pro forma cash balance of approximately A$14.489 million. ✔ Funds will be used to advance the commercialisation of EXO-NET research tools and SubB2M cancer monitoring tests, progress development of pipeline diagnostics and expedite research of high-value cancer therapeutics. Go to https://lnkd.in/gQ8JhHTR to read more. #INOVIQ #EXONET #Biotech #SmallCaps #Investors #CapitalRaise #Exosomes #Therapeutics #Diagnostics #CancerResearch #LifeSciences

$BCLI #NurOwn #ALS Exciting developments Brainstorm Cell Therapeutics! Our Phase 3B trial preparations for NurOwn are progressing well. We're diligently building a strong foundation for a successful launch. Your unwavering support fuels our determination to make a difference in the lives of those affected by ALS. Together, we're one step closer to achieving this goal. As many in the biotech industry know, bringing a new therapy to market can be a complex journey. Securing the necessary funding is crucial. We're actively exploring various avenues, including non-dilutive grants as we have done in the past. Your support, whether through investment, partnership, or simply spreading awareness, is invaluable. Let's work together to overcome challenges and create a brighter future for ALS patients and their families. #BetterTogether #ALSresearch #biotech #clinicaltrials #funding #healthcare

The Biotech industry is buoyant with Innovation and great investment stories! Engrail Therapeutics: $157M Series B to fund neuropyschiatric treatments for anxiety, depression and PTSD. Healx: Raised $47 million in a Series C financing round. The U.S. FDA has cleared their IND application to advance HLX-1502 in Phase 2 clinical trial in Neurofibromatosis Type 1 (NF1). Exscientia: Announced last week that they entered into a definitive agreement with Recursion (Nasdaq: RXRX). This proposed combination of Exscientia’s Generative AI drug design and Recursion’s high throughput target biology will help them deliver better treatments to patients faster and at a lower cost. Mirador Therapeutics: Raised $400M Series A to develop precision medicines for inflammatory and fibrotic diseases. #Biotech #Investment #Venturecapital #Funding #Innovation #Research

I am excited to join #HCWainwright Global Investment Conference, NYC, 9-11 September. It feels like this year confirms that if we focus our efforts, anything can become a reality or an approved drug! 👏🏻 Incredible approvals for Eli Lilly and Company (Kisunla™ for early symptomatic Alzheimer’s disease) and Day One Biopharmaceuticals’ OJEMDA for relapsed pediatric low-grade glioma. 🥁 Real break-through in precision oncology, where we see four solid #tumor-#agnostic approvals fro top pharma companies. 🌈 Solid advancements in CAR-T immunotherapies, from Kyverna Therapeutics, ImmPACT Bio, Cabaletta Bio and early stage developers. While biotech financing rounds are fewer, they’re larger, and investors are looking for innovation and solid market strategies. Look forward to seeing you all in New York next week, and exploring how advancements in drug development, technology, and AI can shape the future of medicine! #Biotech #DrugDevelopment #InvestmentConference #Innovation #Networking #Collaboration

Endeavor BioMedicines 𝘀𝗲𝗰𝘂𝗿𝗲𝘀 $𝟭𝟯𝟮.𝟱 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 𝗳𝘂𝗻𝗱𝗶𝗻𝗴, extending its runway for clinical-stage fibrosis drugs until 2026. Led by CEO John Hood, the company aims to advance its pipeline, notably focusing on a midstage idiopathic pulmonary fibrosis (IPF) drug. New investors include AyurMaya, an affiliate of Matrix Capital Management, along with Fidelity Investments, The Invus Group, @SymBiosis, Velosity Capital and Woodline Partners LP . Hood said Endeavor set out to raise between $𝟳𝟱 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗮𝗻𝗱 $𝟭𝟬𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻,𝗯𝘂𝘁 𝗱𝗲𝗺𝗮𝗻𝗱 𝘀𝗼𝗮𝗿𝗲𝗱 𝗮𝗻𝗱 𝘁𝗵𝗲𝗿𝗲 𝘄𝗮𝘀 𝗮𝘀 𝗺𝘂𝗰𝗵 𝗮𝘀 $𝟮𝟱𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗼𝗻 𝘁𝗵𝗲 𝘁𝗮𝗯𝗹𝗲. https://lnkd.in/evFAr8E7 #BiotechFunding #ClinicalResearch #FibrosisTreatment #BiopharmaInvestment #HealthcareInnovation

Summary: Cartesian Therapeutics, a biotech company, successfully conducted a Phase 2 trial with its experimental therapy for myasthenia gravis, showing promising results in improving patients' conditions. The company plans to further discuss the data with US regulators and has initiated another Phase 2 study for systemic lupus erythematosus. Additionally, Cartesian raised $130 million in funding and appointed Kemal Malik to its board. Hashtags: #CartesianTherapeutics #AutoimmuneDisease #CellTherapy #BioTech #ClinicalTrials Read more here: https://lnkd.in/eiTx4Wb4 BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

🗞𝐓𝐡𝐞 𝐛𝐢𝐠𝐠𝐞𝐬𝐭 𝐩𝐫𝐢𝐯𝐚𝐭𝐞 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐅𝐞𝐛𝐫𝐮𝐚𝐫𝐲 𝟐𝟎𝟐𝟒 "The companies BioAge Labs, Latigo Biotherapeutics, Inc., and Neurona Therapeutics bagged the biggest private biotech #investments in February 2024. Around the world, #oncology and #drug discovery players attracted the biggest funding rounds overall. February 2024 saw fewer private biotech funding rounds take place than in January, with 25 rounds in total compared to January’s 38. However, there was still some impressive #fundraising last month, particularly coming out of North America, as the top 10 biggest rounds went to companies based in the U.S." 𝙏𝙤𝙥 𝙥𝙧𝙞𝙫𝙖𝙩𝙚 𝙗𝙞𝙤𝙩𝙚𝙘𝙝 𝙞𝙣𝙫𝙚𝙨𝙩𝙢𝙚𝙣𝙩𝙨 𝙗𝙮 𝙡𝙤𝙘𝙖𝙩𝙞𝙤𝙣: ✅North America: 17 Rounds - 1,222 ($M) ✅Europe: 7 Rounds - 100 ($M) ✅Asia/Pacific: 1 Round - 42 ($M) 👉 Full article: https://lnkd.in/eecmG3-m Source: Labiotech.eu #biotech #investment #medicines #europe #USA #asia #funding

Might Reunion Neuroscience's $103M Series A mark the end of a drought in funding for private psychedelic biotechs? Aside from Lykos Therapeutics' $100M+ Series A earlier this year, we haven't seen these levels of funding for private co's since the likes of GH Research plc's $125M Series B and atai Life Sciences' $157M Series D back in 2021. It's also quite the turnaround for Reunion, which appeared to have become mired in a patent-related dispute with Mindset Pharma (acquired by Otsuka) and a challenging financial situation. And, it marks another occasion where larger funds have shown appetite to dip their toes in the psychedelic drug development niche, with Novo Holdings co-leading the round.

📢 Funding News: £35 Million Series A Financing 📢 Today, we announce our Series A financing round led by Forbion, alongside our founding investors SV Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). The funds will be used to advance our small molecule somatic expansion inhibition therapy for Huntington’s disease. Our lead programme, MutSβ inhibitor is expected to enter the clinic in 2026. In connection with the financing, we welcome Rogier Rooswinkel, General Partner at Forbion to the LoQus23 Board of Directors. At LoQus23, we are investigating small molecule drugs that could stop #DNAinstability and slow #neurodegeneration in #HuntingtonsDisease. We look forward to progressing our pipeline with the support of our investors, so make sure you’re following LoQus23 Therapeutics Ltd on LinkedIn to stay up to date. 👉 Visit our new website to read the press release and find out more by using the link in the comments below. #financing #venturecapital #drugdevelopment #UKbiotech

USD 90 million for next-gen multifunctional precision immunotherapies: TOP 100 Swiss Scale-up Bright Peak Therapeutics secures its Series C. Congratulations to the team - best of success onwards! https://lnkd.in/eAGeqdfj About: Bright Peak is rapidly advancing a robust portfolio of next-generation, multi-functional, cytokine-based immunotherapies for the treatment of patients with cancer and autoimmune disease. The company accomplishs this by leveraging our world-class protein engineering capabilities and our unique cell-free technology platform to chemically synthesize and conjugate novel protein therapeutics that reflect state-of-the-art insights into cytokine and immune checkpoint biology. The financing round was led by Johnson & Johnson Innovation JJDC Inc, with new investors Venrock, KB Investment, and Northleaf Capital Partners also contributing. Returning investors include founding investor Versant Ventures, along with Fidelity Management And Research Company, RA Capital Management, Qatar Investment Authority, The Invus Group, and Alexandria Venture Investments. Bright Peak Therapeutics was ranked among the TOP 100 Swiss Startups in 2022. #TOP100SSU #SwissStartups